Fig. 3From: Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeuticsTrispecific antibody. Usually created by using variable domain genes if specific monoclonal antibodies. In this case, antigen-binding site 1 is bivalent and engages with an antigen on effector cell, antigen-binding sites 2 and 3 engage antigens 1 and 2 on tumor cellsBack to article page